Fungi have been regarded as an attractive source for discovering new bioactive compounds. 1,2 Several bioactive metabolites from fungi, such as penicillins, cephalosporins, mevastatin and lovastatin, have been the important products of pharmaceutical industry. 3 With the aim of searching for bioactive metabolites from fungi, our studies of fungi imperfeci from a variety of ecological groups have resulted in the discovery of several kinds of new natural products with antitumor activity. [4] [5] [6] As part of our continuous screening for more active secondary metabolites from soil-derived fungi imperfeci, a new stachybotrin congener, named stachybotrin G (1) and a known metabolite, stachybotrin (2) were obtained from Stachybotrys parvispora strain HS-FG-843. Here, the report details the fermentation, isolation, structure elucidation and bioactivity of the new compound.
The strain was grown and maintained on potato dextrose agar slant and incubated for 6-7 days at 24°C. The stock culture was transferred into 1 l Erlenmeyer flasks containing 250 ml of the seed medium and incubated at 24°C for 24 h, shaken at 150 r.p.m. Then, 1 l of the culture was transferred into a 50-l fermentor containing 30 l of producing medium consisting of peptone 0.5%, potato starch 0.5%, yeast extract 0.2%, NaCl 0.4%, KH 2 PO 4 0.1%, MgSO 4 ·7H 2 O 0.05%, CaCO 3 0.2% (pH 6.2-6.4). The fermentation was carried out at 24°C for 7 days stirred at 100 r.p.m. with an aeration rate of 900 l of air per hour.
The final 30 l of broth from 50 l fermentor was filtered and the resulting cake was washed with water (3 l) and subsequently extracted with MeOH (3 l). The supernatant and the wash water were subjected to a Diaion HP-20 resin (Mitsubushi Chemical Co., Ltd., Tokyo, Japan) column eluting with 95% EtOH (5 l). The MeOH extract and the EtOH eluents were evaporated under reduced pressure to a volume of 1 l at 50°C and the resulting concentrate was extracted three times using an equal volume of EtOAc. The combined EtOAc phase was concentrated under reduced pressure to yield a mixture (15 g). The mixture was subjected to a Sephadex LH-20 gel (GE Healthcare, Glies, UK) column eluted with (2) isolated from this strain and stachybotrins D-F obtained from the sponge-derived fungus Stachybotrys chartarum MXH-X73 7 suggested that 1 belonged to the stachybotrin series containing a combination of a spirobenzofuran system with a sesquiterpenoid drimane nucleus.
Further detailed analysis of the NMR data revealed that the differences between 1 and stachybotrin (2) were that the isolated C-24 and C-25 methylene groups in 2 were replaced by the five carbon signals at δ C 169. and those constants showed the axial orientation of H-24. Biogenetically, the relative configuration of 1 was assigned by analogy with 2 and stachybotrins D-F. Therefore, the structure of 1 was determined (Figure 1) , and named stachybotrin G.
Compound 2 was also obtained as a white amorphous powder. Its structure was elucidated as stachybotrin by the comparison of the 1 H and 13 C NMR data (Table 1) of 2 with the NMR data reported by Kamalov et al. 8, 9 The cytotoxicity of compounds 1 and 2 were assayed in vitro against the human lung carcinoma A549 cell lines by the CCK8 colorimetric method as described in our previous papers. 10, 11 As a result, compounds 1 and 2 exhibited cytotoxic activity with IC 50 values of 17.4 and 9.5 μg ml − 1 , respectively. A new stachybotrin congener from a soil fungus S. parvispora D Zhou et al
